ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Monday, October 22, 2018

9:00AM-11:00AM
Abstract Number: 1568
Azathioprine and Mycophenolate for Management of Sjögren’s Syndrome-Related Interstitial Lung Disease: A Retrospective Cohort Study
Sjögren's Syndrome – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 1561
B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Sjögren's Syndrome – Basic and Clinical Science Poster
9:00AM-11:00AM
Abstract Number: 1518
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity
9:00AM-11:00AM
Abstract Number: 1526
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity
9:00AM-11:00AM
Abstract Number: 1495
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1802
Behcet’s Disease in the Southwestern United States
Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 1459
Bone Erosion Volume Changes Measured By HR-pQCT at 3-Months after Initiation of Anti-TNF Treatment Predicted Erosion Volume Changes at 1-Year in RA
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1597
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
9:00AM-11:00AM
Abstract Number: 1755
Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States
Vasculitis – ANCA-Associated Poster I
9:00AM-11:00AM
Abstract Number: 1283
Calcium Pyrophosphate Crystal Deposition in a Cohort of 48 Patients with Gitelman Syndrome
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1139
Can Body Composition Explain the Sex Disparity in Risk of Osteoarthritis?
Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function
9:00AM-11:00AM
Abstract Number: 1258
Can Patients Enter Medical History Data By Self-Report Directly into an Electronic Medical Record (EMR)? “Private Medical History” (PMH) Software for Physician Report in EMR Format and Patient Storage to Correct and Update Medical History for Any EMR
Measures and Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 1164
Canadians’ Views about Using Big Data in Health Research from a National Online Survey: A Partnership of Patient-Consumers and Researchers
Epidemiology and Public Health Poster II – ARHP
9:00AM-11:00AM
Abstract Number: 1325
Canakinumab Treatment in Adult-Onset Still’s Disease: Case Series
Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis
9:00AM-11:00AM
Abstract Number: 1589
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
  • «Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology